![Foundation Medicine and Natera Announce the Launch of FoundationOne®Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use | Business Wire Foundation Medicine and Natera Announce the Launch of FoundationOne®Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use | Business Wire](https://mms.businesswire.com/media/20230108005039/en/794671/23/FMI_horizontal.jpg)
Foundation Medicine and Natera Announce the Launch of FoundationOne®Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use | Business Wire
![Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer | Molecular Diagnosis & Therapy Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer | Molecular Diagnosis & Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40291-019-00408-y/MediaObjects/40291_2019_408_Fig5_HTML.png)
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer | Molecular Diagnosis & Therapy
![Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study | JCO Precision Oncology Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study | JCO Precision Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/po/2018/po.2018.2/po.18.00074/20181101/images/large/po.18.00074ta1.jpeg)
Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study | JCO Precision Oncology
FoundationOne®CDx Technical Information Foundation Medicine, Inc. 150 Second Street, Cambridge, MA 02141 Phone: 617.418.2200 I
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors | PLOS ONE
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors | PLOS ONE
![Diagnostics | Free Full-Text | Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital Diagnostics | Free Full-Text | Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital](https://www.mdpi.com/diagnostics/diagnostics-13-01619/article_deploy/html/images/diagnostics-13-01619-g001-550.jpg)